20.500.12556/DiRROS-8638
Zaviralci angiogeneze v zdravljenju možganskih tumorjev
Angiogenesis Inhibitors in Brain Tumor Treatment
Maligni gliomi so po histologiji in po odgovoru na zdravljenje heterogena skupina možganskih tumorjev. Standardno zdravljenje glioblastomov je kombinacija obsevanja in konkomitantne kemoterapije s temozolomidom. Antiangiogena strategija predstavlja nov pristop v zdravljenju malignih gliomov, saj so to zelo dobro ožiljeni tumorji. Predklinični podatki kažejo, da je rast teh tumorjev močno odvisna od nastajanja novih žil, te pa spodbujajo dejavniki, ki jih izloča tumor, med njimi tudi endotelni žilni rastni dejavnik (VEGF). Bevacizumab je humanizirano monoklonsko protitelo, ki veže VEGF in je dokazano učinkovit pri številnih solidnih tumorjih. V monoterapiji ali v kombinaciji s citostatiki je učinkovit tudi v zdravljenju glioblastomov, kar so pokazali rezultati kliničnih raziskav. Skupaj z učinkovitostjo zdravljenja se izboljšajo kognitivne funkcije, zmanjša se potreba po kortikosteroidih in izboljša se kakovost življenja. Bevacizumab predstavlja novo možnost zdravljenja bolnikov, pri katerih se glioblastom ponovi oz. napreduje.
Considering the histology of malignant gliomas and their response to treatment, they are regarded as a heterogenous group of brain tumors. Standard treatment is a combination of irradiation and concomitant chemotherapy with temozolomide. A new approach to the treatment of malignant gliomas is antiangiogenic strategy because these tumors are highly vasculated. Preclinical data show that the growth of these tumors depends on the onset of new blood vessels which is stimulated by various factors, such as VEGF (vascular endothelial growth factor), produced by the tumor itself. Bevacizumab is a humanized monoclonal antibody that binds to VEGF. It has been proved to be efficient the treatment of numerous solid tumors. Moreover, bevacizumab is efficient also in the treatment of glioblastomas, applied as monotherapy or in combination with cytostatics, which has been confirmed by the results of several clinical studies. In addition to its efficiency in the treatment glioblastomas, it has also been found to have the capacity of improving the patients' cognitive functions, reducing their need for corticosteroids, thereby also improving their quality of life. Bevacizumab offers a new potential in the treatment of recurrent or advanced glioblastoma.
true
false
true
Slovenski jezik
Angleški jezik
by Authors
Neznano
2018-08-31 13:27:16
2018-08-31 13:27:16
2022-08-16 10:09:41
0000-00-00 00:00:00
2009
0
0
str. 127-129, 153
št. 2
Letn. 13
dec. 2009
0000-00-00
Zaloznikova
Objavljeno
NiDoloceno
0000-00-00
0000-00-00
0000-00-00
616.831-006.6-085
1408-1741
URN:NBN:SI:doc-34GBY615
855419
65324032
RAZ_Ocvirk_Janja_i2009.pdf
RAZ_Ocvirk_Janja_i2009.pdf
1
6C1AADEE0CF7B416FF9B8DBA4487F618
119887de602d8a7a99b4bdb86cc97deb7cf89fe8002d87ee4bcc7307e0946674
545fdd04-17b5-11ed-b6b8-001a4af901a5
20.500.12556/dirros/cb2f8461-521d-457c-a837-d375802357b6
https://dirros.openscience.si/Dokument.php?lang=slv&id=10419
Onkološki inštitut Ljubljana
Onkologija : strokovni časopis za zdravnike
0
0
0